Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum

J Antimicrob Chemother. 1995 Dec;36(6):1013-9. doi: 10.1093/jac/36.6.1013.

Abstract

Thirteen dogs naturally infected with Leishmania infantum showing viscero-cutaneous signs of disease were treated with different dosages of liposomal amphotericin B (AmBisome). The animals were followed clinically and parasitologically over a period of eight months. Dogs which received three to five administrations of AmBisome 3-3.3 mg/kg showed rapid clinical improvement, with regression of lymphadenomegaly and splenomegaly, and cure of skin lesions. The clinical response was similar to that obtained with 14-21 doses of conventional antileishmanial drugs. However, follow-up lymph node aspirates remained positive for Leishmania in all dogs except one, which was treated with the total dose of AmBisome 15 mg/kg. The failure in parasitological cure may be due to inadequate drug targeting to parasitized cells, or to T-cell immune depression characteristic of patent cases of canine leishmaniasis, or to both.

MeSH terms

  • Amphotericin B / adverse effects
  • Amphotericin B / pharmacology*
  • Animals
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / pharmacology*
  • Dog Diseases / drug therapy*
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Carriers
  • Electrophoresis
  • Evaluation Studies as Topic
  • Female
  • Isoenzymes / analysis
  • Leishmania infantum* / enzymology
  • Leishmaniasis, Visceral / drug therapy*
  • Leishmaniasis, Visceral / veterinary*
  • Liposomes
  • Lymph Nodes / parasitology
  • Male

Substances

  • Antiprotozoal Agents
  • Drug Carriers
  • Isoenzymes
  • Liposomes
  • liposomal amphotericin B
  • Amphotericin B